Announcements Trials
Browse Landscape

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 3Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Blood Specimen Collection 121Surveys and Questionnaires 83Observation 50Radiotherapy 40Drug Therapy 35Surgical Procedures, Operative 34Biopsy 31Specimen Handling 28Data Collection 28Watchful Waiting 21Interviews as Topic 20Immune Checkpoint Inhibitors 19Magnetic Resonance Imaging 18Liquid Biopsy 16Immunotherapy 15Magnetic Resonance Spectroscopy 14Standard of Care 13pembrolizumab 12Tomography, X-Ray Computed 12Ultrasonography 11trastuzumab deruxtecan 10lenvatinib 10Radiosurgery 10Nivolumab 10Carboplatin 10Tissue Banks 9Restraint, Physical 9Radiation 9Neoadjuvant Therapy 9Endoscopy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Observational × ravulizumab × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔